By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Willemstraat 5

Breda    4811 AH  The Nederlands
Phone: 31-0-10-763-030-488 Fax: n/a


argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.




CEO: Tim Van Hauwermeiren

CFO: Eric Castaldi

CSO: Hans de Haard

CDO: Torsten Dreier

CMO: Nicolas Leupin


Please click here for Argenx job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Private

Web Site: Argenx


Company News
Argenx Presents Full Data From ARGX-111 Phase Ib Study In Patients With Advanced Cancers Over-Expressing The MET Protein At Best Of ASCO Asia 2017 (Singapore) 7/7/2017 10:38:23 AM
Argenx Receives Second Preclinical Milestone Payment In Collaboration With LEO Pharma 6/20/2017 10:23:50 AM
Argenx Announces Closing Of NASDAQ IPO 5/24/2017 12:40:42 PM
Argenx Announces Full Exercise Of Underwriters' Option To Purchase Additional ADSs 5/19/2017 7:33:53 AM
Argenx Raises Approximately $100 Million Gross Proceeds With NASDAQ IPO 5/18/2017 11:00:38 AM
Argenx Announces Size Of Initial Public Offering In The United States Increased To 5 Million ADSs 5/16/2017 10:48:10 AM
Argenx Announces Launch Of Proposed Initial Public Offering In The United States 5/8/2017 10:52:10 AM
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Myasthenia Gravis 5/4/2017 11:41:02 AM
Argenx Reports First Quarter 2017 Financial Results And Provides Business Update 5/3/2017 11:04:56 AM
Argenx Announces Results Of Annual General Meeting 2017 4/26/2017 10:46:20 AM